Up-regulation of hypoxia-inducible factor 2α in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene

Cancer Research

Volumn 63, Issue 10, 2003, Pages 2675-2680

  Liu, Matt Yu ^a   Poellinger, Lorenz ^b   Walker, Cheryl L ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; CULTURE MEDIUM; EPITHELIUM CELL; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENE TSC 2; GENETIC TRANSCRIPTION; IMMUNOBLOTTING; KIDNEY CARCINOMA; KIDNEY EPITHELIUM; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; ENDOTHELIAL GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; LYMPHOKINES; RATS; REPRESSOR PROTEINS; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037842275     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. 2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol., 15: 551-578, 1999.
2. Huang, L. E., Arany, Z., Livingston, D. M., and Bunn, H. F. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J. Biol. Chem., 271: 32253-32259, 1996.
3. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA, 95: 7987-7992, 1998.
4. Salceda, S., and Caro, J. Hypoxia-inducible factor 1α (HIF-1aα) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem., 272: 22642-22647, 1997.
5. Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y., and Poellinger, L. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J. Biol. Chem., 274: 6519-6525, 1999.
6. Tian, H., McKnight, S. L., and Russell, D. W. Endothelial PAS domain protein 1 (EPASI), a transcription factor selectively expressed in endothelial cells. Genes Dev., 11: 72-82, 1997.
7. Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., and Fujii-Kuriyama, Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA, 94: 4273-4278, 1997.
8. Flamme, I., Frohlich, T., von Reutern, M., Kappel, A., Damert, A., and Risau, W. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 α and developmentally expressed in blood vessels. Mech. Dev., 63: 51-60, 1997.
9. Hogenesch, J. B., Chan, W. K., Jackiw, V. H., Brown, R. C., Gu, Y. Z., Pray-Grant, M., Perdew, G. H., and Bradfield, C. A. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J. Biol. Chem., 272: 8581-8593, 1997.
10. Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., and Harris. A. L. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol., 157: 411-421, 2000.
11. Ferrara, N. VEGF: an update on biological and therapeutic aspects. Curr. Opin. Biotechnol., 11: 617-624, 2000.
12. Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., and Semenza, G. L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol., 16: 4604-4613, 1996.
13. Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., and Ratcliffe, P. J. Hypoxia-inducible factor-I modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA, 94: 8104-8109, 1997.
14. Goldberg, M. A., and Schneider, T. J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem., 269: 4355-4359, 1994.
15. Levy, A. P., Levy, N. S., Wegner, S., and Goldberg, M. A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem., 270: 13333-13340, 1995.
16. Madan, A., and Curtin, P. T. A 24-base-pair sequence 3′ to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer. Proc. Natl. Acad. Sci. USA, 90: 3928-3932, 1993.
17. Kerbel, R. S. Tumor angiogenesis: past, present and the near future. Carcinogenesis (Lond.), 21: 505-515, 2000.
18. Thoenes, W., Storkel, S., and Rumpelt, H. J. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol. Res. Pract., 181: 125-143, 1986.
19. Zbar, B., and Lerman, M. Inherited carcinomas of the kidney. Adv. Cancer Res., 75: 163-201, 1998.
20. Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F. M., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet., 7: 85-90, 1994.
21. Kovacs, G., Akhtar, M., Beckwith, B. J., Bugert, P., Cooper, C. S., Delahunt, B., Eble, J. N., Fleming, S., Ljungberg, B., Medeiros, L. J., Moch, H., Reuter, V. E., Ritz, E., Roos, G., Schmidt, D., Srigley, J. R., Storkel, S., van den Berg, E., and Zbar, B. The Heidelberg classification of renal cell tumours. J. Pathol., 183: 131-133, 1997.
22. Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T. Y., Huang, L. E., Pavletich, N., Chau, V., and Kaelin, W. G. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol., 2: 423-427, 2000.
23. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., and Ratcliffe, P. J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (Lond.), 399: 271-275, 1999.
24. Tanimoto, K., Makino, Y., Pereira, T., and Poellinger, L. Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J., 19: 4298-4309, 2000.
25. 2 sensing. Science (Wash. DC), 292: 464-468, 2001.
26. 2-regulated prolyl hydroxylation. Science (Wash. DC), 292: 468-472, 2001.
27. Bruick, R. K., and McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science (Wash. DC), 294: 1337-1340, 2001.
28. Yu, F., White, S. B., Zhao, Q., and Lee, F. S. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA, 98: 9630-9635, 2001.
29. Wiesener, M. S., Munchenhagen, P. M., Berger, I., Morgan, N. V., Roigas, J., Schwiertz, A., Jurgensen, J. S., Gruber, G., Maxwell, P. H., Loning, S. A., Frei, U., Maher, E. R., Grone, H. J., and Eckardt, K. U. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1α in clear cell renal carcinomas. Cancer Res., 61: 5215-5222, 2001.
30. Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassiliou, E., Oldfield, E. H., Klausner, R. D., and Linehan, W. M. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Sci. USA. 93: 10589-10594, 1996.
31. Turner, K. J., Moore, J. W., Jones, A., Taylor, C. F., Cuthbert-Heavens, D., Han, C., Leek, R. D., Gatter, K. C., Maxwell, P. H., Ratcliffe, P. J., Cranston, D., and Harris, A. L. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res., 62: 2957-2961, 2002.
32. Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., and Plate, K. H. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene, 19: 5435-5443, 2000.
33. Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., Jr., and Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA, 93: 10595-10599, 1996.
34. Eker, R., and Mossige, J. A dominant gene for renal adenomas in the rat. Nature (Lond.), 189: 858-859, 1961.
35. Walker, C., Goldsworthy, T. L., Wolf, D. C., and Everitt, J. Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. Science (Wash. DC), 255: 1693-1695, 1992.
36. Yeung, R. S., Xiao, G. H., Jin, F., Lee, W. C., Testa, J. R., and Knudson, A. G. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc. Natl. Acad. Sci. USA, 91: 11413-11416, 1994.
37. Kobayashi, T., Hirayama, Y., Kobayashi, E., Kubo, Y., and Hino, O. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat. Genet., 9: 70-74, 1995.
38. Hino, O., Klein-Szanto, A. J., Freed, J. J., Testa, J. R., Brown, D. Q., Vilensky, M., Yeung, R. S., Tartof, K. D., and Knudson, A. G. Spontaneous and radiation-induced renal tumors in the Eker rat model of dominantly inherited cancer. Proc. Natl. Acad. Sci. USA, 90: 327-331, 1993.
39. Yeung, R. S., Xiao, G. H., Everitt, J. I., Jin, F., and Walker, C. L. Allelic loss at the tuberous sclerosis 2 locus in spontaneous tumors in the Eker rat. Mol. Carcinog., 14: 28-36, 1995.
40. Kobayashi, T., Urakami, S., Hirayama, Y., Yamamoto, T., Nishizawa, M., Takahara, T., Kubo, Y., and Hino, O. Intragenic Tsc2 somatic mutations as Knudson's second hit in spontaneous and chemically induced renal carcinomas in the Eker rat model. Jpn. J. Cancer Res., 88: 254-261, 1997.
41. Kobayashi, T., Minowa, O., Kuno, J., Mitani, H., Hino, O., and Noda, T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res., 59: 1206-1211, 1999.
42. Onda, H., Lueck, A., Marks, P. W., Warren, H. B., and Kwiatkowski, D. J. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Investig., 104: 687-695, 1999.
43. Gnarra, J. R., Ward, J. M., Porter, F. D., Wagner, J. R., Devor, D. E., Grinberg, A., Emmert-Buck, M. R., Westphal, H., Klausner, R. D., and Linehan, W. M. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl. Acad. Sci. USA, 94: 9102-9107, 1997.
44. Haase, V. H., Glickman, J. N., Socolovsky, M., and Jaenisch, R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. Acad. Sci. USA, 98: 1583-1588, 2001.
45. Urakami, S., Tokuzen, R., Tsuda, H., Igawa, M., and Hino, O. Somatic mutation of the tuberous sclerosis (Tsc2) tumor suppressor gene in chemically induced rat renal carcinoma cell. J. Urol., 158: 275-278, 1997.
46. Satake, N., Urakami, S., Hirayama, Y., Izumi, K., and Hino, O. Biallelic mutations of the Tsc2 gene in chemically induced rat renal cell carcinoma. Int. J. Cancer, 77: 895-900, 1998.
47. Wolf, D. C., Whiteley, H. E., and Everitt, J. I. Preneoplastic and neoplastic lesions of rat hereditary renal cell tumors express markers of proximal and distal nephron. Vet. Pathol., 32: 379-386, 1995.
48. Everitt, J. I., Goldsworthy, T. L., Wolf, D. C., and Walker, C. L. Hereditary renal cell carcinoma in the Eker rat: a rodent familial cancer syndrome. J. Urol., 148: 1932-1936, 1992.
49. Walker, C., Ahn, Y. T., Everitt, J., and Yuan, X. Renal cell carcinoma development in the rat independent of alterations at the VHL gene locus. Mol. Carcinog., 15: 154-161, 1996.
50. Shiao, Y. H., Diwan, B. A., Perantoni, A. O., Calvert, R. J., Zbar, B., Lerman, M. I., and Rice, J. M. Polymerase chain reaction-single-strand conformation polymorphism analysis for the VHL gene in chemically induced kidney tumors of rats using intron-derived primers. Mol. Carcinog., 19: 230-235, 1997.
51. Shiao, Y. H., Rice, J. M., Anderson, L. M., Diwan, B. A., and Hard, G. C. von Hippel-Lindau gene mutations in N-nitrosodimethylamine-induced rat renal epithelial tumors. J. Natl. Cancer Inst., 90: 1720-1723, 1998.
52. Kleymenova, E., Ibraghimov-Beskrovnaya, O., Kugoh, H., Everitt, J., Xu, H., Kiguchi, K., Landes, G., Harris, P., and Walker, C. Tuberin-dependent membrane Localization of polyeystin-1. A functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol. Cell, 7: 823-832, 2001.
53. Walker, C., and Ginsler, J. Development of a quantitative in vitro transformation assay for kidney epithelial cells. Carcinogenesis (Lond.), 13: 25-32, 1992.
54. Perera, A. D., Kleymenova, E. V., and Walker, C. L. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin. Cancer Res., 6: 1518-1523, 2000.
55. Kaelin, Jr., W. G. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer, 2: 673-682, 2002.
56. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F., and Senger, D. R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol., 143: 1255-1262, 1993.
57. Tomisawa, M., Tokunaga, T., Oshika, Y., Tsuchida, T., Fukushima, Y., Sato, H., Kijima, H., Yamazaki, H., Ueyama, Y., Tamaoki, N., and Nakamura, M. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur. J. Cancer, 35: 133-137, 1999.
58. Ferrara, N., and Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev., 18: 4-25, 1997.
59. Duffy, K., Al-Saleem, T., Karbowniczek, M., Ewalt, D., Prowse, A. H., and Henske, E. P. Mutational analysis of the von Hippel-Lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients. Mod. Pathol., 15: 205-210, 2002.
60. Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J. Activation of the HIF pathway in cancer. Curr. Opin. Genet. Dev., 11: 293-299, 2001.
61. Horesovsky, G., Recio, L., Everitt, J., Goldsworthy, T., Wolf, D. C., and Walker, C. p53 status in spontaneous and dimethylnitrosamine-induced renal cell tumors from rats. Mol. Carcinog., 12: 236-240, 1995.
62. Nishiyama, Y., Suwa, H., Okamoto, K., Fukumoto, M., Hiai, H., and Toyokuni, S. Low incidence of point mutations in H-, K- and N-ras oncogenes and p53 tumor suppressor gene in renal cell carcinoma and peritoneal mesothelioma of Wistar rats induced by ferric nitrilotriacetate. Jpn. J. Cancer Res., 86: 1150-1158, 1995.
63. McManus, E. J., and Alessi, D. R. TSC1-TSC2: a complex tale of PKB-mediated S6K regulation. Nat. Cell Biol., 4: E214-216, 2002.
64. Lando, D., Pongratz, I., Poellinger, L., and Whitelaw, M. L. A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1α and the HIF-like factor. J. Biol. Chem., 275: 4618-4627, 2000.
65. Tian, H., Hammer, R. E., Matsumoto, A. M., Russell, D. W., and McKnight, S. L. The hypoxia-responsive transcription factor EPAS1 is essential for catechoIamine homeostasis and protection against heart failure during embryonic development. Genes Dev., 12: 3320-3324, 1998.
66. 2 homeostasis by hypoxia-inducible factor I α. Genes Dev., 12: 149-162, 1998.
67. Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., and Klausner, R. D. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell, 1: 247-255, 2002.
68. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., and Kaelin, W. G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell, 1: 237-246, 2002.